Trial · NCT01653665
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neutrophil phagocytosis | 2 days after GMCSF/placebo administration | neutrophil phagocytic capacity will be measured as the percentage of neutrophils ingesting 2 or more zymosan particles ex vivo |
| Secondary | neutrophil phagocytic capacity on alternate study days | 0 - 9 days | Measured on alternate days and also as 'area under the curve' over the study period |
| Secondary | Other measures of neutrophil function | 0-9 days | May include but not limited to: ROS generation, migration capacity and apoptotic rate |
| Secondary | Monocyte HLA-DR expression | 0-9 days | Alternate days by flow-cytometry |
| Secondary | Serum measures of inflammatory response | 0-9 days | May include but not limited to: cytokine levels |
| Secondary | Sequential organ failure assessment (SOFA) | up to end of study participation, a maximum of 30 days for each participant | |
| Secondary | Length of ICU stay | Up to end of participation in study, a maximum of 30 days | |
| Secondary | Incidence of ICUAIs (Intensive care unit acquired infection) | Up to end of study participation, a maximum of 30 days for each patients | As defined by hospitals in europe link for infection control surveillance (HELICS) |
| Secondary | All cause mortality | 30 days post randomisation | |
| Secondary | Number of days of mechanical ventilation | Up to end of study participation, a maximum of 30 days | |
| Secondary | Blood sample analysis | 0-9 days | To measure safety of study medication from blood samples, which will include measures of Full blood count, white cell count (including differential), U\&Es and LFTs, development of neutralising antibodies to GMCSF |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01653665/registered